Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Autoimmune phenomena following SARS-CoV-2 vaccination

Yuval Ishay\textsuperscript{a,b,1}, Ariel Kenig\textsuperscript{a,1}, Tehila Tsemach-Toren\textsuperscript{a,c}, Radgonde Amer\textsuperscript{d}, Limor Rubin\textsuperscript{a,e}, Yoav Hershkovitz\textsuperscript{a}, Fadi Kharouf\textsuperscript{a,c,*}

\textsuperscript{a} Department of Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
\textsuperscript{b} Gastroenterology Unit, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
\textsuperscript{c} Rheumatology Unit, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
\textsuperscript{d} Department of Ophthalmology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
\textsuperscript{e} Allergy and Clinical Immunology Unit, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel

\textbf{ARTICLE INFO}

\textbf{Keywords:}
COVID-19
SARS-CoV-2
Vaccines
Autoimmunity
BNT162b2

\textbf{ABSTRACT}

Vaccines represent an attractive possible solution to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Widespread vaccine distribution has yet to occur in most countries, partially due to public concerns regarding possible side effects. While studies indicate the vaccine is exceptionally safe, rare systemic side effects remain possible. In Israel, where a large percentage of the population has been rapidly vaccinated, such adverse events may be more apparent. We report a series of patients presenting with de-novo or flares of existing autoimmune conditions associated with the Pfizer BNT162b2 mRNA SARS-CoV-2 vaccine. All patients were assessed in our tertiary care center in Israel and had no history of previous SARS-COV-2 infection. We observed that while immune phenomena may occur following vaccination, they usually follow a mild course and require modest therapy. We briefly expound on the theoretical background of vaccine related autoimmunity and explore future research prospects.

1. Introduction

Vaccines as triggers of autoimmunity is a controversial subject. Many vaccine related immunological adverse events have been described; for example, evidence for an increased risk of Guillain-Barre syndrome following Influenza vaccine, an association between systemic lupus erythematosus and the papilloma vaccine, and episodes of immune demyelination after hepatitis B vaccine were all previously suggested\cite{1,2}. Although direct causation is debatable, the association is plausible.

Detecting immunological adverse reactions to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is of great public and scientific interest. This is especially the case for the mRNA-based vaccines available, the first mRNA-based vaccines entering mass use.

By March 2021, more than half of the adult (>16 years) population in Israel had been vaccinated with at least one dose of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine (BioNTech and Pfizer). Studies suggest significant efficacy in preventing COVID-19 and reducing disease severity. This tremendous vaccination rate provides an opportunity to detect rare adverse events not reported in the original trial\cite{3}. Here, we present eight cases of autoimmune phenomena following COVID-19 vaccination, suggesting a possible association between these novel vaccines and autoimmunity.

2. Methods

All patients have been treated during the first 3 months of 2021 by

\textsuperscript{*} Corresponding author. at: Department of Medicine and the Rheumatology Unit, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem 91120, Israel.

E-mail address: fadik@hadassah.org.il (F. Kharouf).

\textsuperscript{1} The first two authors contributed equally.
3. Case presentations

Herein, we describe the cases we find to be most informative on post-vaccine immune phenomena. Pertinent details are repeated in table, and several similar cases are summarized in table form only (Table 1). All references to vaccine refer to the BNT162B2 mRNA vaccine.

### 3.1 Symmetric polyarthritis

A 49-year-old male (patient #1) presented with a 2-day history of bilateral hand pain, swelling, and stiffness. His complaints appeared three days after receiving the first dose of the vaccine. His medical history was notable for dyslipidemia, non-alcoholic fatty liver disease, and active smoking. Physical examination revealed prominent symmetrical arthritis in the metacarpophalangeal and proximal interphalangeal joints. No history of gout, psoriasis, inflammatory bowel disease or recent infection was elicited. Blood tests showed slightly elevated C-reactive protein (CRP). Antinuclear antibody (ANA), Rheumatoid factor (RF), and parvovirus IgM, tested immediately following the acute symptoms, were negative. Anti-citrullinated protein antibody (ACPA) was mildly elevated. Hand radiographs and chest X-ray were unremarkable.

While the acute development of symptoms in proximity to vaccination argue against a diagnosis of rheumatoid arthritis, the distribution pattern and ACPA positivity support the diagnosis. Autoimmune polyarthritis, possibly representing early rheumatoid arthritis, induced or triggered by the vaccine, was diagnosed. Therapy with prednisone 10 mg brought immediate relief. Upon gradual steroid tapering over a period of 8 weeks, polyarthralgia reappeared, necessitating the commencement of methotrexate therapy.

### 3.2 Left eye panuveitis as a manifestation of Behçet’s disease flare

A 28-year-old male patient (patient #2) presented with a 2-day history of left eye pain, redness, and blurred vision. His symptoms

| Patient number, age, and sex | Autoimmune phenomenon | Time between vaccination and symptom onset | Vaccine dose | Relevant investigations | Treatment(outcome in parenthesis) |
|-----------------------------|-----------------------|-------------------------------------------|-------------|------------------------|-----------------------------------|
| 1, 49 y/o, Male             | Symmetric polyarthritis | 3 days | First (Second uneventful under prednisone 10 mg) | CRP 1.3 mg/dL, Hand radiographs and CXR: Normal, ANA, RF, and parvovirus IgM: Negative, ACPA: Positive | Prednisone 10 mg per day (Resolution of symptoms). Flared upon gradual tapering over 8 weeks, thus methotrexate was added |
| 2, 28 y/o, Male             | Left eye panuveitis (Exacerbation of Behçet’s disease) | 10 days | First (Second uneventful under prednisone 40 mg) | CRP 1.4 mg/dL, ESR 70 mm/hr, CRP 2.75 mg/dL, ECG: Known lateral wall T-wave inversions | Topical corticosteroids, IV corticosteroids, azathioprine (Resolution of symptoms and normalization of WBC count and CRP levels) |
| 3, 34 y/o, Male             | Pericarditis (Recurrent) | 1 day | First (Second uneventful under prophylactic NSAIDs) | CRP 8.7 mg/dL, ESR 48 mm/hr | NSAIDs and colchicine (Resolution of symptoms and normalization of WBC count and CRP levels) |
| 4, 60 y/o, Male             | Temporal arteritis-like disease | 3 days | First (Second uneventful under prednisone 15 mg) | CRP 29 mg/dL, ESR 70 mm/hr | Prednisone 20 mg per day (Resolution of symptoms) |
| 5, 60 y/o, Male             | FUO                    | A few hours | Second (First uneventful) | CRP 0.7 mg/dL, CRP 0.8 mg/dL, ECG: Normal, TTE: Mild pericardial effusion | No specific treatment (Spontaneous clinical resolution; repeat CRP within 2 days declined to 12.4 mg/dL) |
| 6, 37 y/o, Female           | Oligoarthritis         | 3 weeks | Second (First uneventful) | CRP 0.7 mg/dL | NSAIDs (Resolution of symptoms) |
| 7, 37 y/o, Male             | Pericarditis (new-onset) | 10 days | First (Second uneventful) | CRP 0.8 mg/dL | NSAIDs and colchicine (Resolution of symptoms) |
| 8, 22 y/o, Male             | Myocarditis            | 2 weeks | Second (First uneventful) | CRP 0.7 mg/dL, ECG: Normal, TTE: Mild pericardial effusion | NSAIDs and colchicine (Resolution of symptoms and normalization of WBC count, CRP, and troponin levels) |

---

**Abbreviations:** (reference range where relevant): ACPA, anti-citrullinated protein antibodies; AION, anterior ischemic optic neuropathy; ANA, antinuclear antibodies; ANCA, anti-neutrophil cytoplasmic antibody; c-ANCA, cytoplasmic ANCA; CRP, C-reactive protein (0–0.5 mg/dL); CT, computed tomography; CXR, chest X-ray; CMV, cytomegalovirus; ECG, electrocardiograph; ESR, erythrocyte sedimentation rate (0–20 mm/hr); FUO, fever of unknown origin; HIV, human immunodeficiency virus; NSAIDs, non-steroidal anti-inflammatory drugs; p-ANCA, perinuclear ANCA; PCR, polymerase chain reaction; RF, rheumatoid factor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TTE, transthoracic echocardiography; US, ultrasound; WBC, white blood cells (3.79–10.33 cells/μL); y/o, year-old; CK creatine phosphokinase (46–161 U/L).
began 10 days after receiving the first dose of the vaccine. The patient’s medical record was notable for Behçet’s disease, diagnosed four years earlier, manifesting with oral aphthous ulcers, pericarditis, and erythema nodosum. Familial Mediterranean fever (FMF) was previously ruled out, in the absence of typical episodes of fever and abdominal pain. During the preceding months, the disease was quiescent, being maintained on colchicine therapy, 0.5 mg twice daily.

Blood tests showed leukocytosis and elevated CRP and erythrocyte sedimentation rate (ESR). Ophthalmologic evaluation revealed severe left eye panuveitis compatible with Behçet uveitis, probably vaccine induced. No other systemic signs of disease activity were present. Pulse intravenous methylprednisolone (1 g/day for 5 days) was instituted in addition to intensive topical steroid therapy. Oral corticosteroids were subsequently introduced with azathioprine. There was remarkable clinical recovery, with resolution of leukocytosis and decline in CRP levels.

### 3.3. Pericarditis (Recurrent)

A 34-year-old male (patient #3) presented with pleuritic chest pain one day after receiving the first dose of the vaccine. This was followed shortly by an episode of symptomatic atrial fibrillation (AF). The patient’s medical history was notable for recurrent pericarditis, appearing two years earlier, and a single, brief episode of AF, attributed to stress. The absence of episodes of fever and abdominal pain ruled out a diagnosis of FMF. The patient was well-controlled on colchicine therapy, with the last pericarditis flare occurring 15 months pre-vaccination. Current symptoms resembled the well-known previous inflammatory events.

Blood tests showed mild leukocytosis and elevated CRP; cardiac biomarkers were unremarkable. Electrocardiography (ECG) revealed lateral wall T-wave inversions, known from previous episodes. Trans-thoracic echocardiography (TTE) showed a mild pericardial effusion.

A flare of pericarditis was suspected. As the disease was completely quiescent in the previous months, an association with the vaccine was considered. The patient was started on a course of non-steroidal anti-inflammatory drugs (NSAIDs) and underwent successful pharmacologic cardioversion. Therapy with NSAIDs was continued, with resolution of symptoms and normalization of the leukocyte count and CRP levels.

### 3.4. Temporal arteritis-like disease

A 60-year-old male (patient #4) presented with a 3-day history of frontotemporal headaches, accompanied by diffuse arthralgia, general weakness, and blurred vision. No fever or jaw claudication were present. The patient’s medical record was notable for metabolic syndrome and gout.

While physical examination was normal, blood tests revealed elevated CRP and ESR. The combination of frontotemporal headaches, blurred vision, diffuse arthralgia, general weakness, and elevated inflammatory markers raised suspicion of temporal arteritis. Neurological evaluation was normal, and head computed tomography (CT) angiography showed no ischemic lesions. Ophthalmologic examination and temporal ultrasonography were unremarkable.

Upon thorough history taking, the patient mentioned that his complaints started three days following the first dose of the vaccine. A vaccine-related syndrome resembling temporal arteritis was suspected, owing to the suggestive clinical picture. Therapy with prednisone 20 mg per day led to immediate clinical improvement.

### 3.5. Fever of unknown origin (FUO)

A 60-year-old male (patient #5) presented with a 2-week history of malaise and high-grade fever, progressing to diffuse arthralgia, myalgia, frontal headache, throat pain, and bilateral hand swelling. A generalized pruritic rash was also present. The patient’s complaints began several hours after receiving the second dose of the vaccine. His medical record was unremarkable.

Physical examination revealed bilateral shoulder tenderness, pitting edema on the dorsal aspect of the hands, and remnants of an urticarial rash on the flexor surface of the arms. Blood tests showed elevated CRP and ESR; creatinine phosphokinase (CPK), lactate dehydrogenase (LDH), thyroid function tests, and ferritin levels were normal. A broad microbiologic workup was negative, including blood cultures, serologies for Brucella, Coxiella Burnetti, Cytomegalovirus, and human immunodeficiency virus (HIV), as well as a nasopharyngeal PCR for SARS-CoV-2. Whole-body CT scan and temporal ultrasonography were normal.

Since a thorough investigation revealed no evident etiology, a post-vaccine immune syndrome was suspected. The patient improved clinically over several days without specific intervention, paralleling a decline in CRP levels.

### 4. Discussion

COVID-19 has wreaked global havoc economically and politically and has had a far-reaching impact on worldwide health. Countries and persons have had to radically change their way of life. Across the globe, people yearn for a return to normalcy. While ongoing studies attempt to fill the physician’s armamentarium with effective drugs, they are far from the panacea that will allow restoration of normal life. Vaccines carry the potential benefit of reducing disease transmission and disease severity a-priori. This is especially true if they can protect at-risk populations from severe disease and the attendant burden on health systems.

In Israel, where health management organizations with electronic health records serve virtually the entire population, distribution of vaccines has been managed with striking rapidity and completeness. Procuring the Pfizer BNT162b2 2-dose mRNA vaccine, Israel has to date vaccinated over 5 million persons with both vaccine doses. This represents a substantial percentage of the qualifying population and approaches 60% of the total 9.2 million persons population. Real life results concerning vaccine efficacy in Israel have been recently published in peer-reviewed journals [4,5], and results match up to those presented in clinical trials. Despite the success of the Israeli vaccine drive, it has not gone without skepticism. Specifically, concern has been garnered regarding the relatively novel technology of mRNA vaccines and has persisted despite concerted efforts from government and private organizations to refute misinformation and provide assurance regarding vaccine safety.

While the vaccine appears to be effective and safe, side effects have been observed. Most side effects have been mild and associated with short-term reactions to the vaccine, including injection site reactions, fever and flu-like symptoms [3]. A small fraction of vaccinated persons nonetheless had more severe autoimmune manifestations following the first or second vaccines doses. While the benefits of vaccination far outweigh the risks in the vast majority of cases, it is prudent to be acquainted with possible autoimmune phenomena observed in the post-vaccine period.

The manifestation drawing the most attention in the post-vaccination period is myocarditis, especially those rare reports of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common. The true added incidence of severe myocarditis. Mild cases of perimyocarditis, such as the ones presented herein, are likely more common.
following vaccination. Some have nonetheless gone on to manifest prolonged symptoms in patterns appropriate for diagnosis of a chronic autoimmune disease or have had clear-cut exacerbations of known diseases.

The mechanisms of immune activation underlying these events are unknown, but we may draw on previous experience and pre-clinical data.

Exacerbation of inflammatory or autoimmune conditions following infection is not a new concept and has been suggested and demonstrated in different settings [7–9]. As the vaccine exerts its protective action by eliciting an immune inflammatory response, this could be channeled to initiate or exacerbate hyperinflammatory changes in certain vulnerable settings.

Some vaccine adjuvants – the substances lending immunogenicity to the vaccine – have been noted to act via induction and activation of the NLR pyrin domain containing 3 (NLRP3) inflammasome [10]. mRNA vaccines, BNT162b2 included, exhibit a property of self-adjuvantation, the mRNA acting as both antigen and adjuvant. They are recognized by endosomal toll-like receptors (TLRs) and cytosolic inflammasome components (MDA5, RIG-I, NOD2 and PKR), inciting inflammation and immunity [11]. In murine models, lipid nanoparticles in the SARS-CoV-2 mRNA vaccines have been demonstrated to trigger inflammatory reactions by several mechanisms, including the NLRP3 inflammasome, acting as an impromptu adjuvant and possibly accentuating inflammation [12]. It is interesting, then, to note that the NLRP3 inflammasome has been shown to vary according to degrees to be involved in the pathogenesis of inflammation in pericarditis, rheumatoid arthritis, and arthritis [13–15].

An alternative explanation may depend on the exact molecular makeup of SARS-CoV-2, partially shared by the protein expressed after mRNA translation. COVID-19 has been known to sometimes cause myocardiitis and pericarditis [16,17]. These manifestations have also been associated with the vaccine – and have not been largely associated with other vaccines. It is possible that certain self-antigens, expressed more widely in the myopericardium, share a structural similarity with the S protein. These antigens may then trigger an immune response targeted at these antigens. Notably, molecular mimicry has been suggested as a mechanism in COVID-19 related immune phenomena, where viral proteins have elicited immune cross-reactivity with human tissue [18,19]. This cross reactivity is dependent on environmental factors and genetic predisposition, such as immune tolerance deficit following aberrant major histocompatibility complex (MHC) class II antigen presentation to autoreactive T cells [2].

Finally, the adjuvant theory, or bystander effect, states that immune activation stems from the presence of an exposed autodigen in the setting of a pro-inflammatory or pathogenic context. Exact characterization of the immune response triggered by the BNT162b2 has not, to our knowledge, been completely elaborated. Intracellular mRNA or the translated fragment of the SARS-CoV-2 spike protein may trigger components aimed at detecting danger associated molecular patterns, such as TLRs. Activation of TLR7 and TLR8 especially, and downstream signaling via type I interferon production, has been suggested as the driving mechanism [20]. The spike protein fragment, itself likely to be inherently immunogenic [21], may be translocated to the plasma membrane. The context of a xenoprotein embedded in the plasma membrane of a cell in which TLRs and similar proteins have become activated, may trigger an immune response aimed at components of the cell. Similar effects have been implicated in viral infection [22]. Whether any of these theories are true and whether a single theory explains all instances of post-vaccine autoimmunity remains unknown. As different vaccines will permeate different nations, data will accumulate, and comparisons will become possible. Future vaccines may be further refined and less prone to cause side effects, or we will be more able to determine who is at greater risk of developing side effects. Alternatively, sober future analysis may reveal no added burden of autoimmune manifestations occurs in the post-vaccine period.

Our study has several limitations. The preliminary nature of our report necessarily lends itself to biases including salience bias of post-vaccine presentations and selection bias of patients seeking medical attention more often post-vaccination. With over 5 million persons vaccinated in Israel in the preceding months and over a million yearly visits to the Hadassah medical centers, these events are likely exceedingly rare. As a case-series study, the lack of a control group further disallows definitive statements. We nonetheless believe our report may be of value to clinicians, especially those treating patients with established autoimmune or autoinflammatory disease, in this nascent era of COVID-19 vaccines.

CRediT authorship contribution statement

Yuval Ishay: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing. Ariel Kenig: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing. Tehila Tsennach-Toren: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing. Radgonde Amer: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing. Limor Rubin: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing. Yoav Hershkovitz: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing. Fadi Karrouf: Conceptualization, Methodology, Software, Data curation, Writing - original draft, Visualization, Investigation, Supervision, Validation, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] J. Mouchet, F. Salvo, E. Ranchi, E. Poluzzi, I.C. Antonazzo, F. De Ponti, B. Béguad, Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis, Vaccine 36 (12) (2018) 1548–1555.
[2] Y. Segal, Y. Shoenfeld, Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction, Cell. Mol. Immunol. 15 (6) (2018) 589–594.
[3] F.P. Polsack, S.J. Thomas, N. Ritchin, J. Abelson, A. Gurman, S. Lockhart, J-L. Perez, G. Perez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, A. W. Kalina, D. Cooper, R.W. Frenck, L. H. Hammit, O. Tureci, H. Nell, A. Schaefer, S. Ünal, D.B. Trennan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, W.C. Gruber, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med. 383 (27) (2020) 2603–2615.
[4] N. Dagan, N. Barda, E. Keften, O. Miron, S. Perchik, M.A. Katz, M.A. Hernán, M. Lipitch, B. Reiss, R.D. Balicer, BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N. Engl. J. Med. (2021).
[5] S. Benenson, Y. Oster, M.I. Cohen, R. Nir-Paz, BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers, N. Engl. J. Med. (2021).
[6] W.T. Ma, C. Chang, M.E. Gershwin, Z.X. Lian, Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review, J. Autoimmun. 83 (2017) 95–112.
[7] M. Lipitch, P. Langerovitz, Y. Shoenfeld, The role of infection in inflammatory bowel disease: initiation, exacerbation and protection, Isr. Med. Assoc. J. 11 (9) (2009) 558–565.
[8] K.S. Tan, R.L. Lim, J. Liu, H.H. Ong, V.J. Tan, H.F. Lim, K.F. Chung, I.M. Adcock, V. T. Chow, D.Y. Wang, Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases: Novel Mechanisms and Insights From the Upper Airway Epithelium, Front. Cell Dev. Biol. 8 (2020) 99.
[9] M. Vanheusden, B. Broux, S.P.M. Welten, L.M. Peeters, E. Panagioti, B. Van Wijmeersch, V. Somers, P. Stinissen, R. Aens, N. Helliens, Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation, Sci. Rep. 7 (1) (2017) 662.
[10] S. Reinke, A. Thakur, C. Garitan, J.S. Bezbradica, A. Milicic, Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants, Vaccines (Basel) 8 (3) (2020).

[11] J.R. Teijaro, D.L. Farber, COVID-19 vaccines: modes of immune activation and future challenges, Nat. Rev. Immunol. 21 (4) (2021) 195–197.

[12] S. Ndeupen, Z. Qin, S. Jacobsen, H. Estanbouli, A. Bouten, B.Z. Igarta, The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory, Cold Spring Harbor Laboratory, 2021.

[13] A.G. Mauro, A. Bonaventura, A. Vecchie, E. Mezzaroma, S. Carbone, P. Narayan, N. Potere, A. Cannatà, J.F. Paolini, R. Bassani, F. Montecucco, G. Sinagra, B.W. Van Tassel, A. Abbate, S. Tolò, The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches, JACC: Basic to Translational Science 6 (2) (2021) 137–150.

[14] C. Guo, R. Fu, S. Wang, Y. Huang, X. Li, M. Zhou, J. Zhao, N. Yang, NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis, Clin. Exp. Immunol. 194 (2) (2018) 231–243.

[15] N. Tamura, Y. Maejima, T. Matsumura, R.B. Vega, E. Amiya, Y. Ito, Y. Shiheido-Watanabe, T. Ashikaga, I. Komuro, D.P. Kelly, K. Hirao, M. Isobe, Single-Nucleotide Polymorphism of the MLX Gene Is Associated With Takayasu Arteritis, Circ. Geno. Precision Med. 11 (10) (2018) e002296.

[16] R. Kumar, J. Kumar, C. Dely, S.A. Edroos, Acute pericarditis as a primary presentation of COVID-19, BMJ Case Rep. 13 (8) (2020) e237617.

[17] C. Dagrenat, F. Sauer, G. Jochum, S. Ulh, H. Heyer, O. Keller, F. Goiorani, P. Couppie, P. Leddet, Observational cohort study of pericarditis associated to COVID-19 affection, Arch. Cardio. Dis. Supp. 13 (1) (2021) 165.

[18] A. Vojdani, D. Kharrazian, Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases, Clin. Immun. (Orlando, Fla.) 217 (2020) 108480.

[19] D. Kanduc, Y. Shoenfeld, On the molecular determinants of the SARS-CoV-2 attack, Clin. Immun. (Orlando, Fla.) 215 (2020) 108426.

[20] T. Velikova, T. Georgiev, SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis, Rheumatol. Int. 41 (3) (2021) 509–518.

[21] S. Ravichandran, E.M. Coyle, L. Klenow, J. Tang, G. Grubbs, S. Liu, T. Wang, H. Golding, S. Khurana, Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits, Sci. Transl. Med. 12 (550) (2020) eaabc3539.

[22] T.-S. Kim, E.-C. Shin, The activation of bystander CD8+ T cells and their roles in viral infection, Exp. Mol. Med. 51 (12) (2019) 1–9.